Abstract
Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 1143-1145 |
| Number of pages | 3 |
| Journal | Human Vaccines and Immunotherapeutics |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2012 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
Cite this
Inter-tumor heterogeneity. / Cusnir, Mike; Cavalcante, Ludmila.
In: Human Vaccines and Immunotherapeutics, Vol. 8, No. 8, 01.08.2012, p. 1143-1145.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inter-tumor heterogeneity
AU - Cusnir, Mike
AU - Cavalcante, Ludmila
PY - 2012/8/1
Y1 - 2012/8/1
N2 - Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.
AB - Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.
UR - http://www.scopus.com/inward/record.url?scp=84866131656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866131656&partnerID=8YFLogxK
U2 - 10.4161/hv.21203
DO - 10.4161/hv.21203
M3 - Article
C2 - 22854659
AN - SCOPUS:84866131656
VL - 8
SP - 1143
EP - 1145
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
IS - 8
ER -